Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), as amended, Glenmark Pharmaceuticals has informed that Sridhar Gorthi (DIN: 00035824), Devendra Raj Mehta (DIN: 01067895), Brian Tempest (DIN: 00101235) and Bernard Munos (DIN: 05198283) have retired as Independent Directors of the Company from end of the day on 31st March, 2024, consequent to the completion of their second term of office as Independent Directors. The Board placed on record it’s deep appreciation for the valuable contributions made by the above-mentioned Independent Directors during their tenure as Independent Directors. Consequent to the aforesaid retirement, the committees of the Board have been re-constituted as details enclosed. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are provided in Annexure-A.
The above information is a part of company’s filings submitted to BSE.
